L.M. Rademaker , R. Gal , A.M. May , M.C.T. Batenburg , F. van der Leij , R.M. Bijlsma , H.M. Verkooijen , A. Doeksen , M.F. Ernst , D.J. Evers , C.C. van der Pol , E.M. Monninkhof
{"title":"Side-effects in women treated with adjuvant endocrine therapy for breast cancer","authors":"L.M. Rademaker , R. Gal , A.M. May , M.C.T. Batenburg , F. van der Leij , R.M. Bijlsma , H.M. Verkooijen , A. Doeksen , M.F. Ernst , D.J. Evers , C.C. van der Pol , E.M. Monninkhof","doi":"10.1016/j.breast.2025.104416","DOIUrl":null,"url":null,"abstract":"<div><div>Many women with breast cancer prematurely discontinue adjuvant endocrine therapy, leading to increased mortality. We performed a cross-sectional survey (n = 456) within the Dutch UMBRELLA-cohort to gain insight into the prevalence of side-effects and its association with premature discontinuation. Almost all current endocrine therapy users experienced side-effects (92.7 %), most frequent were vasomotor- and musculoskeletal symptoms. The most reported reason for premature discontinuation was side-effects (88.1 %). Former treatment with chemotherapy was associated with more reported side-effects (97.2 % vs 82.5 %, ORadj 6.31), but less premature discontinuation of endocrine therapy (18.6 % vs 28.6 %, p-value 0.016).</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"80 ","pages":"Article 104416"},"PeriodicalIF":7.9000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0960977625000359","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/11 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Many women with breast cancer prematurely discontinue adjuvant endocrine therapy, leading to increased mortality. We performed a cross-sectional survey (n = 456) within the Dutch UMBRELLA-cohort to gain insight into the prevalence of side-effects and its association with premature discontinuation. Almost all current endocrine therapy users experienced side-effects (92.7 %), most frequent were vasomotor- and musculoskeletal symptoms. The most reported reason for premature discontinuation was side-effects (88.1 %). Former treatment with chemotherapy was associated with more reported side-effects (97.2 % vs 82.5 %, ORadj 6.31), but less premature discontinuation of endocrine therapy (18.6 % vs 28.6 %, p-value 0.016).
许多患有乳腺癌的妇女过早停止辅助内分泌治疗，导致死亡率增加。我们在荷兰的umbrella队列中进行了一项横断面调查（n = 456），以深入了解副作用的发生率及其与过早停药的关系。几乎所有目前的内分泌治疗使用者都有副作用（92.7%），最常见的是血管舒缩和肌肉骨骼症状。过早停药的主要原因是副作用（88.1%）。先前化疗治疗与更多报告的副作用相关（97.2% vs 82.5%, ORadj 6.31），但更少过早停止内分泌治疗（18.6% vs 28.6%， p值0.016）。
期刊介绍：
The Breast is an international, multidisciplinary journal for researchers and clinicians, which focuses on translational and clinical research for the advancement of breast cancer prevention, diagnosis and treatment of all stages.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
